Latest News
-
Feature
The aducanumab revolution
As the controversial new Alzheimer’s drug makes its way from research settings to the clinic, practitioners brace for a potential sea change in...
-
From the Journals
Young adults with epilepsy face higher mental illness risks
“The high rates of anxiety, depression, and suicidality underscore the need for better integration of mental health provision into epilepsy care...
-
From the Journals
Large vessel stroke linked to AstraZeneca COVID vaccine
Three cases occurred in two women and one man in their 30s or 40s and involved blockages of the carotid and middle cerebral artery.
-
From the Journals
Psychosis, depression tied to neurodegeneration in Parkinson’s
Lewy body scores were not associated with any neuropsychiatric symptom, the researchers found.
-
From the Journals
Cannabinoids promising for improving appetite, behavior in dementia
Early evidence suggests that cannabinoids may also be beneficial for pain, sleep, and aggression.
Conference Coverage
-
Conference Coverage
Almost half of patients with migraine are reluctant to seek care
Common reasons for failure to seek treatment included believing that migraine was not severe enough to warrant a consultation, worries about cost...
-
Conference Coverage
Fremanezumab fails posttraumatic headache test
The anti-CGRP antibody provided no benefit, despite success in other headache types.
-
Conference Coverage
A large proportion of migraine patients are not offered preventive treatment
Among patients eligible for preventive therapy, more than a third were not offered this option, fewer than 10% were currently taking preventive...
-
Conference Coverage
Migraine linked to more COVID-19 infections, symptoms but less health care utilization
People with migraine are either more susceptible to contracting COVID-19, or they may be more sensitive to the development of symptoms once COVID-...
-
Conference Coverage
Ubrogepant effective for acute migraine even with preventive monoclonal antibody therapy
Despite sharing similar mechanisms, the use of ubrogepant for acute migraine attacks in people already taking CGRP-targeting monoclonal antibody...
-
Conference Coverage
e-TNS device passes at-home test
A phase 3 study showed the Cefaly device was particularly effective against most bothersome migraine symptoms.
-
Conference Coverage
Moving more, sitting less vital for migraine patients
Encouraging patients with migraine to regularly physically exercise is important to managing their symptoms and overall health, but so is simply...
-
Conference Coverage
LAAOS III: Surgical LAA closure cuts AFib stroke risk by one-third
The finding ‘opens a new paradigm’ for stroke prevention in atrial fibrillation and should change clinical guidelines, experts say.
Literature Review
-
Literature Review
Many comatose TBI patients recover consciousness during rehab
“Caution is warranted in consideration of withdrawing or withholding life-sustaining therapies in patients with severe TBI and disorder of...
-
Literature Review
Sustained long-term benefit of gene therapy for SMA
A particular gene therapy provides long-lasting benefits with a favorable safety profile for children with spinal muscular atrophy, new follow-up...
-
Literature Review
Deep brain stimulation is effective over the long haul
STN-DBS continues to be effective for motor complications for longer than 15 years, reducing time spent with dyskinesia by 75% and time spent in...
-
Literature Review
Neurologists brace and prepare for long-COVID fallout
Data that have accumulated since the COVID-19 outbreak suggest that at least 1 in 3 people who are initially infected may be long-haulers.
Guidelines
-
Guidelines
New AHA/ASA guideline on secondary stroke prevention
Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in...
-
Guidelines
AHA: Physical activity best first-line for high BP, cholesterol
Advice to sit less and move more is a critical component of first-line treatment for patients with mild to moderate hypertension and elevated...
News
-
News
FDA expands rimegepant indication to include migraine prevention
Rimegepant is currently the only migraine medication approved to both treat acute migraine attacks and help prevent future migraine attacks.
FDA/CDC
-
FDA/CDC
FDA clears next-generation DBS system for movement disorders
“Until now, sensing capability and directional leads have not been available in the same DBS system.”
Hitting a Nerve
-
Hitting a Nerve
A high-stakes numbers game
Whether Aduhelm succeeds or fails will all be in the numbers.